NAD+ in a Peptide Protocol: Tracking and Stacking

NAD+ is not a peptide, but it's tracked alongside them

NAD+ (nicotinamide adenine dinucleotide) is a cofactor — a molecule that supports enzyme function across cellular metabolism. It is not a peptide. But because it's commonly administered via subcutaneous injection in longevity-focused clinics and because it's frequently stacked with peptides like CJC-1295/Ipamorelin and BPC-157, it shows up in peptide protocol tracking conversations.

This article covers the practical tracking aspects of NAD+ in a multi-compound protocol. We don't make claims about longevity outcomes — the evidence base for NAD+'s longevity effects in humans is still emerging.

What NAD+ actually does

NAD+ is a cofactor for several enzyme classes critical to cellular metabolism:

• Sirtuins (SIRT1–SIRT7) — proteins involved in DNA repair, metabolism, and gene regulation
• PARPs (poly-ADP-ribose polymerases) — DNA damage repair
• CD38 — immune function, intracellular signaling

NAD+ levels naturally decline with age. The longevity hypothesis: restoring NAD+ levels supports sirtuin activity and DNA repair, slowing aspects of biological aging. Animal studies have shown promise; human trials are smaller and shorter than what's available for, e.g., GLP-1 agonists.

Forms: precursor (oral) vs. NAD+ direct (injection/IV)

Most practitioners and biohackers use either oral precursors (cheaper, easier) or SubQ NAD+ (more invasive, faster onset). IV NAD+ is typically reserved for higher-dose protocols or specific clinical contexts (some clinics offer it for addiction recovery, post-COVID protocols, etc.).

SubQ NAD+: typical dosing and tracking

Common practitioner protocols for SubQ NAD+ injection:

• Loading: 100–300 mg/day SubQ for 1–2 weeks
• Maintenance: 50–100 mg, 2–5×/week

NAD+ injections are often described as "burning" or "intense" at the injection site — this is a known property, not a sign of contamination. Slow injection over several minutes reduces the burning sensation. Some users dilute SubQ NAD+ with bacteriostatic water to spread the dose volume; others inject neat from prepared vials.

Tracking NAD+ alongside peptides

For tracking purposes, NAD+ behaves like another SubQ injection in your protocol. Each dose log captures:

• Date and time
• Dose (mg)
• Volume (mL or units, depending on concentration)
• Injection site
• Notes (any noteworthy reactions, intensity of burning, etc.)

The site rotation question matters as much as for any daily SubQ. NAD+'s tendency to cause local burning means many users prefer larger SubQ areas (abdomen, thigh) over smaller-volume sites.

Stacking NAD+ with peptides: timing considerations

NAD+ doesn't have known direct interactions with the common stacked peptides (BPC-157, CJC/Ipa, GLP-1s), but practical timing considerations apply:

• NAD+ + CJC-1295/Ipamorelin: CJC/Ipa requires fasted state. NAD+ doesn't have a strict fasting requirement but is often given in the morning by routine. Stacking morning fasted CJC/Ipa with morning NAD+ requires deciding which to inject first — typically the smaller-volume, faster-clearing compound (CJC/Ipa) is injected first to keep its window clean.
• NAD+ + BPC-157: No timing conflict; both can be injected at the same time (different sites) or any cadence.
• NAD+ + GLP-1: Weekly GLP-1 + daily NAD+; no direct interaction documented. Tracking complexity from cadence mismatch.

Oral precursors (NMN, NR): different tracking model

If you're using oral NMN or NR instead of SubQ NAD+, tracking is simpler: daily oral capsule with no injection logistics. The dose log captures date and dose; no reconstitution, units, or site rotation.

The oral vs. injectable choice is largely about cost, convenience, and clinical preference. Bioavailability differs (oral precursors take cellular conversion; SubQ NAD+ is direct), but whether this produces meaningfully different outcomes in humans is not well established.

Cost and access

NAD+ for injection is typically obtained through:

• Compounding pharmacies (with prescription) — typical pricing ~$100–250/month
• Longevity-focused clinics that provide injections + supply — bundled pricing
• Research-only suppliers — same source-evaluation issues as research peptides; see the peptide source evaluation guide

Oral NMN/NR is sold as a dietary supplement (no prescription needed), generally $30–100/month depending on brand and dose.

What we're not doing here

We're not making claims about life extension, biological age reversal, or longevity outcomes. The evidence base for NAD+ in humans is emerging — animal data is promising, human trials are smaller and shorter than what's available for well-established compounds. Whether the price and inconvenience of SubQ NAD+ is worth it over oral precursors, and whether either meaningfully impacts longevity, are open questions.

The tracking principles, however, are the same as for any other compound in your protocol: log each dose accurately so you and your provider have clear data.